For over 19 years, the COR-Medical team has been introducing innovative medical technologies in Ukraine, including continuous glucose monitoring (CGM) systems that open new possibilities for blood sugar control. However, it is important for us not only to make modern technologies accessible to Ukrainian patients, but also to evaluate their effectiveness from a scientific perspective.

That is why, ahead of World Diabetes Day on November 14, we are presenting the interim results of a clinical study evaluating the effectiveness of CGM Sibionics systems, conducted at the clinical base of Bogomolets National Medical University. Specialists analyzed data from patients with prediabetes over the first three months of observation and recorded a clear positive trend in the continuous monitoring group compared to traditional glucometers.

Interim results: from project launch to initial clinical data

At the initial stage, 40 patients with verified prediabetes were included in the interim analysis. Participants were divided into two equal groups of 20 individuals:

• The first group used CGM Sibionics continuous glucose monitoring systems, which measure glucose levels in interstitial fluid in real time and transmit data to a mobile app without the need for repeated finger pricks.
  
  
• The second group performed self-monitoring of blood glucose using traditional capillary glucometers.

.            

A key condition of the study was the strict standardization of baseline parameters: patients in both groups received identical standard recommendations regarding dietary adjustments and daily physical activity levels. This allowed researchers to isolate and assess the specific additional benefit of continuous patient access to their glycemic profile.

Comparative dynamics of key health indicators

After three months of observation, researchers evaluated changes in three primary parameters: glycated hemoglobin (HbA1c) levels, body mass index (BMI), and waist circumference. Patients using CGM Sibionics demonstrated more pronounced improvements across all three metrics.

The summary of changes over the 3-month observation period is presented in the table below:

Parameter	Glucometer (Traditional)	CGM Sibionics	Effect Ratio	Statistical Significance (p)
HbA1c Reduction	-0.28%	-0.42%	1.5x greater reduction in the CGM group	p = 0.406
BMI Reduction	-0.67 kg/m²	-1.37 kg/m²	Approx. 2x greater reduction in the CGM group	p = 0.162
Waist Circumference Reduction	-2.35 cm	-4.43 cm	Nearly 1.9x greater reduction in the CGM group	p = 0.034 (significant)

A detailed analysis of the obtained data reveals the following trends:

1. Glycemic Control (HbA1c): In the CGM group, glycated hemoglobin levels decreased by 0.42 percentage points compared to 0.28 percentage points in the glucometer group. Thus, the positive trend in the CGM group was 1.5 times stronger.
2. Body Mass (BMI): The body mass index reduction among CGM Sibionics users was 1.37 kg/m², compared to 0.67 kg/m² in the traditional monitoring group. Body mass reduction in the CGM group outperformed the control group nearly twofold.
3. Abdominal Obesity (Waist Circumference): The most impressive and statistically significant results were observed in waist circumference reduction. Patients using CGM Sibionics lost an average of 4.43 cm around the waist, compared to 2.35 cm among patients using glucometers. Waist circumference reduction in the CGM group was nearly 1.9 times greater, demonstrating a statistically significant difference between the groups (p = 0.034).

Beyond sugar control: CGM as a driver of behavioral change

The results of the first three months confirm an important hypothesis put forward by the researchers: the CGM Sibionics system functions not merely as a measuring device, but as a powerful tool for patient education and psychological support.

When a person with prediabetes sees their body's real-time reaction to specific foods, portion sizes, or evening walks displayed graphically on their smartphone screen, it fosters a high level of awareness. Unlike episodic glucometer readings, real-time continuous monitoring helps patients adhere more closely to dietary and physical activity recommendations, ultimately resulting in a statistically significant reduction in visceral fat and waist circumference.

Future outlook and study continuation

The interim data obtained are preliminary and require further confirmation in a larger sample of participants. The scientific project is ongoing, with a total of 160 individuals planned for enrollment.

Patient monitoring includes extended laboratory testing (evaluating fructosamine and C-peptide levels), body composition analysis via bioimpedance spectrometry, and tracking of daily physical activity. The resulting dataset will provide a comprehensive understanding of the clinical and practical advantages of continuous monitoring technology in the early stages of carbohydrate metabolism disorders.

The official representative of the CGM Sibionics system in Ukraine—the COR-Medical team—continues to provide technical and service support for the project. Participation in the study is free of charge for patients, and the final results will be published for the medical community and the general public once data collection and processing are complete. To learn more about tracking glucose levels in real time using a smartphone, see the article "Sibionics Glucose Monitoring System."